-
- Stephen K. Brannan, MD
-
- John D. Young
By Karen Roman
Slate Medicines, Inc. said Stephen K. Brannan, MD, and John D. Young were appointed to the company’s Board of Directors.
Dr. Brannan has over 25 years of clinical development experience in central nervous system disorders and previously served as Chief Medical Officer of Karuna Therapeutics, the company said. He also held clinical and medical leadership roles at Forum Pharmaceuticals, Takeda, Novartis, Cyberonics (now LivaNova) and Eli Lilly, mentioned Slate Medicines.
Mr. Young has more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, and most recently as Group President and Chief Business Officer, the company stated. He retired from Pfizer in 2022 after a 35-year career and currently serves on the boards of Novartis AG and Johnson Controls International, said Slate Medicines.
READ MORE
Agenda with Keynotes 1789 Capital, Better Home: 6th Palm Beach CorpGov Forum Nov 4-5
“Stephen has helped bring multiple CNS treatments from the clinic to approval, while John has shaped corporate strategy, partnerships and portfolio decisions at a leading global pharmaceutical company,” said Gregory Oakes, MBA, Slate Medicines CEO. “Their guidance will be invaluable as we advance SLTE-1009 as well as our portfolio and work to bring much-needed new treatment options to migraine patients who remain underserved by current therapies.”
Dr. Brannan is board-certified in psychiatry, and received his AB from Harvard University and his MD from The University of Texas Southwestern Medical School. Mr. Young holds a BSc in Biological Sciences from the University of Glasgow and an MBA from Strathclyde Graduate Business School.
Never Miss our Weekly Highlights HERE
Contact:
Click HERE to follow us on LinkedIn
